Myalgia

20

Pipeline Programs↗

0

Active Trials↗

11

Companies Involved↗

Myalgia is an emerging landscape with 20 programs across 11 companies. The most active players are Furiex Pharmaceuticals, Inc, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., AbbVie. 11 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

70/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Furiex Pharmaceuticals, Inc

1 program

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

2 programs

AbbVie

1 program

Eli Lilly

1 program

Averitas Pharma, Inc.

1 program

Bayer

1 program

Pipeline

Programs by Phase

Preclinical5

Dexketoprofen

Pamukkale University

Nifedipine

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Baclofen/diazepam

Dr. John A. Thiel Medical Professional Corporation

Etodolac

Wyeth-Lederle Vaccines

Thiocolchicoside

Sanofi

Phase 1

No programs

Phase 23

Duloxetine

Alnylam Pharmaceuticals

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

PPD10558

Furiex Pharmaceuticals, Inc

Phase 31

Cisatracurium

AbbVie

Approved11

Baricitinib

Eli Lilly

Naproxen

Alnylam Pharmaceuticals

Capsaicin

Averitas Pharma, Inc.

Flurbiprofen

Pharmacia and Upjohn

Ketoprofen

Wyeth-Lederle Vaccines

Analysis

Trial Status

12

clinical trials

Completed7 · 58%

Unknown status2 · 17%

Terminated2 · 17%

Withdrawn1 · 8%

Clinical Trials

Trial Activity

12 trials

Duloxetine for Succinylcholine-induced Postoperative Myalgia

Completed·—·Phase 2/3·NCT03037073·70 enrolled

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

Completed·FFuriex Pharmaceuticals, Inc·Phase 2·NCT01279590·282 enrolled

Evaluation of the Effects of Treatments Applied to Patients With Facial Myalgia on Occlusion Parameters

Completed·YYuzuncu Yil University·N/A·NCT05261971·60 enrolled

Addition of Pudendal Blocks to Pelvic Floor Physical Therapy for the Treatment of Pelvic Floor Tension Myalgia

Completed·UUniversity of California, Irvine·N/A·NCT00928564·40 enrolled

Effects of Cisatracurium on Succinylcholine-induced Fasciculations and Myalgia

Completed·—·Phase 3·NCT02481193·90 enrolled

The Effect of Pretreatment With Roc on Succinylcholine Myalgias

Completed·IIndiana University·Phase 3·NCT04581395·300 enrolled

Effect of Aerobic Interval Training With Vitamin D Supplement on Functional Capacity and Perceived Myalgia

Completed·—·N/A·NCT04319289·45 enrolled

IV Ibuprofen for Post-Electroconvulsive Therapy Myalgia

Terminated·RRutgers, The State University of New Jersey·Phase 4·NCT01200069·14 enrolled

Vitamin D Replacement: The Effect on Statin-Related Myalgias

Terminated·—·N/A·NCT01022398·4 enrolled

A Study Examining the Use of Vaginal Nifedipine With Pelvic Floor Physical Therapy for Levator Myalgia and Pelvic Pain

Withdrawn·VVanderbilt University·N/A·NCT01586286

Baclofen/Diazepam Supps for Treatment of Pelvic Floor Myalgia

Unknown status·—·N/A·NCT03427216·60 enrolled

Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain

Unknown status·UUniversity of Cincinnati·Phase 4·NCT02022722·36 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)